{"id":71084,"date":"2024-10-01T17:26:00","date_gmt":"2024-10-01T15:26:00","guid":{"rendered":"https:\/\/www.ipsen.com\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/"},"modified":"2025-02-28T13:25:37","modified_gmt":"2025-02-28T11:25:37","slug":"irinotecan-liposomal-compare-au-traitement-standard","status":"publish","type":"lay_language","link":"https:\/\/www.ipsen.com\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/","title":{"rendered":"Une \u00e9tude comparant les effets de l’irinot\u00e9can liposomal au traitement standard chez les personnes dont le cancer du poumon s’est aggrav\u00e9 apr\u00e8s le traitement initial."},"content":{"rendered":"\n

Onivyde<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":11,"template":"","lay_language_category":[74110],"class_list":["post-71084","lay_language","type-lay_language","status-publish","has-post-thumbnail","hentry","entry"],"acf":[],"yoast_head":"\nUne \u00e9tude comparant les effets de l'irinot\u00e9can liposomal au traitement standard chez les personnes dont le cancer du poumon s'est aggrav\u00e9 apr\u00e8s le traitement initial. - Global<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Une \u00e9tude comparant les effets de l'irinot\u00e9can liposomal au traitement standard chez les personnes dont le cancer du poumon s'est aggrav\u00e9 apr\u00e8s le traitement initial. - Global\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-28T11:25:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/11\/08172710\/Image1-2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1949\" \/>\n\t<meta property=\"og:image:height\" content=\"1118\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/\",\"name\":\"Une \u00e9tude comparant les effets de l'irinot\u00e9can liposomal au traitement standard chez les personnes dont le cancer du poumon s'est aggrav\u00e9 apr\u00e8s le traitement initial. - Global\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/11\/08172710\/Image1-2.png\",\"datePublished\":\"2024-10-01T15:26:00+00:00\",\"dateModified\":\"2025-02-28T11:25:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/#primaryimage\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/11\/08172710\/Image1-2.png\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/11\/08172710\/Image1-2.png\",\"width\":1949,\"height\":1118},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Une \u00e9tude comparant les effets de l’irinot\u00e9can liposomal au traitement standard chez les personnes dont le cancer du poumon s’est aggrav\u00e9 apr\u00e8s le traitement initial.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Une \u00e9tude comparant les effets de l'irinot\u00e9can liposomal au traitement standard chez les personnes dont le cancer du poumon s'est aggrav\u00e9 apr\u00e8s le traitement initial. - Global","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/","og_locale":"fr_FR","og_type":"article","og_title":"Une \u00e9tude comparant les effets de l'irinot\u00e9can liposomal au traitement standard chez les personnes dont le cancer du poumon s'est aggrav\u00e9 apr\u00e8s le traitement initial. - Global","og_url":"https:\/\/www.ipsen.com\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/","og_site_name":"Global","article_modified_time":"2025-02-28T11:25:37+00:00","og_image":[{"width":1949,"height":1118,"url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/11\/08172710\/Image1-2.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/","url":"https:\/\/www.ipsen.com\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/","name":"Une \u00e9tude comparant les effets de l'irinot\u00e9can liposomal au traitement standard chez les personnes dont le cancer du poumon s'est aggrav\u00e9 apr\u00e8s le traitement initial. - Global","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/11\/08172710\/Image1-2.png","datePublished":"2024-10-01T15:26:00+00:00","dateModified":"2025-02-28T11:25:37+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/#primaryimage","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/11\/08172710\/Image1-2.png","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/11\/08172710\/Image1-2.png","width":1949,"height":1118},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/lay-language\/irinotecan-liposomal-compare-au-traitement-standard\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Une \u00e9tude comparant les effets de l’irinot\u00e9can liposomal au traitement standard chez les personnes dont le cancer du poumon s’est aggrav\u00e9 apr\u00e8s le traitement initial."}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/lay_language\/71084","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/lay_language"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/lay_language"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/11"}],"version-history":[{"count":2,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/lay_language\/71084\/revisions"}],"predecessor-version":[{"id":75782,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/lay_language\/71084\/revisions\/75782"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media\/71083"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=71084"}],"wp:term":[{"taxonomy":"lay_language_category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/lay_language_category?post=71084"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}